u/tomas_kimani

Personal importation provisions exist, are narrow, and carry conditions. Any summary of them here should be checked against the current official wording rather than a forum post.

Went looking for independent results on this and found a handful across the whole site. That is the honest state of the evidence.

Reference intervals are typically the central 95% of a reference population. By construction one person in twenty falls outside one on any given test without anything being wrong.

Push back: a value just outside a reference interval is a common finding in healthy people. It is a reason to repeat.

Agreed — units are volume. Once that lands, the rest of the arithmetic is one division.

That comparison crosses two labs with different assays. The difference you are describing may be the method.

Correcting my own comment: the two draws were 6 weeks apart, not the figure I gave earlier.

Correction: that gives 10 units, not what you have written. 10mg into 1mL is 10mg/mL and the division follows from there.

Not convinced. Amylin signalling is not a GLP-1 pathway and the mechanism you are proposing conflates them.

nausea that arrives on day two and fades by day four is the standard shape

Adding one thing to this: the appetite effect and the scale run on separate clocks, so both halves can be true at once.

the ladder exists because the gut needs the time, not because the pharmacy likes paperwork

Disagree — that is an obesity trial endpoint and this thread is about glycaemic control.

Are you quoting a diabetes trial or an obesity one?

check the trial population before quoting a result at somebody

Continuous monitoring shows the shape: postprandial excursions, overnight behaviour and time in range.

Adding the obvious one — bring the export, not the single number, to whoever manages this.

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

Have you checked the shortage database directly?

more water is not more drug, it is the same drug in a bigger volume

stalling at 1.0mg is information, not a verdict

I would not extrapolate the tolerability profile from the monotherapy arm to the combination.

This is the distinction that keeps this board honest — different axis, not a stronger version of the same one.

Is there any independent purity data on this compound that you have seen?

That figure is the 68-week trial mean, not a weekly rate. Dividing it by the weeks gives you a number that does not mean anything.

phase 3 data will change most of what gets said here

nothing containing this is approved as a standalone product

a mean is not a promise

Nothing containing this compound is approved as a standalone product, and research-use-only material is not approved for human use.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

the food noise going quiet is the effect people actually describe

STEP-1 ran 68 weeks and landed just under 15% mean body weight change on 2.4mg. It is an average of a wide distribution, not a target you have missed.

Careful — that arithmetic is wrong. 5mg in 2mL is 2.5mg/mL, so 1mg draws to 40 units, not what you wrote.

Minor fix — the half-life is about a week, not about a day. The rest of your point stands.